Vir Biotechnology, Inc. $VIR Shares Bought by Hudson Bay Capital Management LP

Hudson Bay Capital Management LP lifted its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 31.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 911,882 shares of the company’s stock after acquiring an additional 215,882 shares during the quarter. Hudson Bay Capital Management LP’s holdings in Vir Biotechnology were worth $5,207,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in VIR. AQR Capital Management LLC increased its position in Vir Biotechnology by 2,088.4% during the 1st quarter. AQR Capital Management LLC now owns 268,297 shares of the company’s stock worth $1,739,000 after purchasing an additional 256,037 shares during the period. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Vir Biotechnology in the first quarter valued at approximately $359,000. Goldman Sachs Group Inc. boosted its stake in shares of Vir Biotechnology by 43.6% in the first quarter. Goldman Sachs Group Inc. now owns 742,674 shares of the company’s stock valued at $4,813,000 after buying an additional 225,544 shares in the last quarter. Woodline Partners LP grew its holdings in Vir Biotechnology by 245.6% during the first quarter. Woodline Partners LP now owns 466,737 shares of the company’s stock worth $3,024,000 after acquiring an additional 331,701 shares during the period. Finally, Focus Partners Wealth raised its position in Vir Biotechnology by 15.3% in the first quarter. Focus Partners Wealth now owns 19,317 shares of the company’s stock worth $125,000 after acquiring an additional 2,566 shares in the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.

Vir Biotechnology Stock Down 3.0%

VIR opened at $9.10 on Friday. The firm has a market cap of $1.27 billion, a P/E ratio of -2.88 and a beta of 1.65. The business’s fifty day simple moving average is $8.06 and its 200 day simple moving average is $6.58. Vir Biotechnology, Inc. has a 52 week low of $4.16 and a 52 week high of $10.94.

Vir Biotechnology (NASDAQ:VIR) last released its earnings results on Monday, February 23rd. The company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.11. The company had revenue of $64.07 million for the quarter, compared to analyst estimates of $19.91 million. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 49.31%. The firm’s quarterly revenue was up 417.8% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.76) EPS. As a group, equities analysts expect that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Insider Activity at Vir Biotechnology

In other Vir Biotechnology news, CEO Backer Marianne De sold 19,039 shares of Vir Biotechnology stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $7.45, for a total value of $141,840.55. Following the completion of the sale, the chief executive officer directly owned 1,035,466 shares of the company’s stock, valued at approximately $7,714,221.70. The trade was a 1.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Verneuil Vanina De sold 13,700 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $9.82, for a total value of $134,534.00. Following the transaction, the executive vice president directly owned 112,982 shares in the company, valued at approximately $1,109,483.24. This represents a 10.81% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 177,546 shares of company stock valued at $1,522,174. Company insiders own 16.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on VIR. Wall Street Zen raised Vir Biotechnology from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Raymond James Financial raised shares of Vir Biotechnology from an “outperform” rating to a “strong-buy” rating and set a $19.00 price target on the stock in a research note on Tuesday, February 24th. Evercore reiterated an “outperform” rating and issued a $18.00 price objective on shares of Vir Biotechnology in a research note on Tuesday, February 24th. Leerink Partners reissued an “outperform” rating and set a $20.00 price objective on shares of Vir Biotechnology in a report on Thursday, February 26th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Monday, December 22nd. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Vir Biotechnology presently has an average rating of “Moderate Buy” and an average target price of $20.44.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.